Synthesis and biodistribution of two potential PET radioligands for dopamine reuptake sites: No-carrier-added 4-(2-[18F]fluoroethyl) and 4- [11C]methyl BTCP-piperazine

Nuclear Medicine and Biology

Volumn 24, Issue 6, 1997, Pages 513-518

  Loustau Then, I ^a,b   Ponchant, M ^a   Fuseau, C ^a   Kamenka, J M ^b   Vignon, J ^b   Crouzel, C ^a  

^a DIF   (France)

^b INSERM   (France)

Author keywords

11C; 18F; BTCP or 1 1(2 benzo(b)thiophenyl)cyclohexyl piperidine BTCP fluoroethyl piperazine or 1 1 (2 benzo(b)thiophenyl)cyclohexyl 4 (2 Fluoroethyl)piperazine BTCP methyl piperazine or 1 l (2 benzo(b)thiophenyl)cyclohexyl 4 methylpiperazine; Dopamine transporter; PET; Reuptake inhibitor

Indexed keywords

1 [1 (2 BENZO[B]THIOPHENYL)CYCLOHEXYL] 4 (2 FLUOROETHYL)PIPERAZINE F 18; 1 [1 (2 BENZO[B]THIOPHENYL)CYCLOHEXYL] 4 METHYLPIPERAZINE C 11; DOPAMINE TRANSPORTER; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG DISTRIBUTION; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; TISSUE DISTRIBUTION;

ANIMALS; CARBON RADIOISOTOPES; DOPAMINE; DOPAMINE AGONISTS; FLUORINE RADIOISOTOPES; MALE; PHENCYCLIDINE; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 0030870863     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)00033-4     Document Type: Article

References (24)

1. Agid Y., Javoy-Agid F. and Ruberg M. (1987) Biochemistry of neurotransmitters in Parkinson's disease. Movement Disorders. Butterworth, London, 166-230.
2. Agid Y. (1991) Brain dopaminergic systems: Imaging with positon emission tomography. (Edited by Baron J. C., Comar D., Farde L., Martinot J. L. and Mazoyer B.) p. 121, Kluwer Academic Publishers.
3. Brooks D. J. (1991) Brain dopaminergic systems: Imaging with positon emission tomography. (Edited by Baron J. C., Comar D., Farde L., Martinot J. L. and Mazoyer B.) p. 121, Kluwer Academic Publishers.
4. 18F]fluorodopa using a regioselective fluorodemercuration reaction. Appl. Radiat. Isot. 45, 25-30.
5. Coderc E., Martin-Fardon R., Vignon J. and Kamenka J. M. (1993) New compounds resulting from structural and biochemical similarities between GBR12783 and BTCP, two potent inhibitors of dopamine uptake. Eur. J. Med. Chem. 28, 893-898.
6. 11C] methyl iodide. Int. J. Appl. Radiat. Isot. 38, 601-603.
7. 18F]fluoro-L-dopa for the in vivo study of intracerebral Dopamine Int. J. Appl. Radiat. Isot. 37, 669-675.
8. 3H]Win 35,428 binding to the dopamine transporter. Neurochem. Int. 21, 581-584.
9. 11C]-CFT and PET in a primate model of parkinsonism. NeuroReport 3, 265-268.
10. Innis R. B, Seibyl J. P., Scanley B. E., Lamelle M., Abidargham A., Wallace E., Baldwin R. M, Zeaponce Y., Zoghlir S. and Wang S. (1993) Single photon emmission computed tomography imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc. Natl. Acad. Sci. USA 90, 11965-11969.
11. Kaufman M. J. and Madras B. K. (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 9, 43-49.
12. 18F] fluoride production. Int. J. Appl. Radiat. Isot. 36, 327-328.
13. 18F]GBR 13119 to the brain dopamine uptake system. Life Sci. 42, 1347-1353.
14. 18F]GBR 13119. Imaging the dopamine uptake system in vivo. Nucl. Med. Biol. 16, 569-576.
15. Kish S. H., Shannack K. and Hornykiewick O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 318, 876-880.
16. 11C)-nomifensine uptake in healthy volunteers and patients with Parkinson's disease using PET. Neurology 39, (suppl. 1) 272-281.
17. 18F]fluoroethyl)piperazine. J. Label. Comp. Radiopharm. 38, 299-308.
18. Mazière B., Coenen H. H., Halldin C., Nagren K. and Pike V. W. (1992) PET radioligands for dopamine receptors and reuptake sites: Chemistry and biochemistry. Nucl. Med. Biol. 19, 497-512.
19. Nys G. and Rekker R. (1973) Statistical analysis of a series of partition coefficients with special reference to the predictability of folding of drug molecules. The introduction of hydrophobic fragmental constants (f-values). Chim. Therap. 5, 521-535.
20. Nys G. and Rekker R. (1974) The concept of hydrophobic fragmental constants (f-values) II. Extension of its applicality to the calculation of lipophilicities of aromatic and heteroaromatic structures. Eur. J. Med. Chem. Chim. Therap. 9, 361-375.
21. 18F]fluoromethyl BTCP and evaluation as a potential PET radioligand for the dopamine transporter in baboons. Nucl. Med. Biol. 20, 727-733.
22. 3H]TCP: A new tool with high affinity for the PCP receptor in rat brain. Brain Res. 280, 194-197.
23. Maurice T., Vignon J., Kamenka J.M. and Chicheportiche R. (1991) Differential interaction of phencyclidine-like drugs with the dopamine uptake complex in vivo. J. Neurochem. 56, 553-559.
24. 3H]BTCP): A new phencyclidine analog selective for the dopamine uptake complex. Eur. J. Pharmacol. 148, 427-436.